vaccine Archives
Rational vaccine design
Sep. 22, 2020—Understanding immunity generated by smallpox vaccine may hold lessons for COVID-19 vaccine development.
Vanderbilt University Medical Center to recruit up to 1,000 volunteers for COVID-19 vaccine Trial
Jul. 15, 2020—In late July, Vanderbilt University Medical Center will begin recruiting up to 1,000 volunteers in a late-stage study of an experimental COVID-19 vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.
VUMC studies provide key positive results for COVID-19 vaccine in early-stage clinical trial
Jul. 14, 2020—An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.
RSV transmission in the Middle East
Nov. 14, 2019—Understanding how RSV is transmitted, which strains dominate and how new strains emerge around the globe will guide better vaccine and anti-viral drug design.
Low oxygen and antibody responses
Apr. 25, 2019—Mark Boothby and colleagues are exploring the factors that contribute to antibody production and quality, which are key to our defense against pathogens and response to vaccines.
A “public” target for HIV
Jun. 8, 2018—Common sequences of antibodies against HIV may be key to developing a successful vaccine strategy for the virus.
New target to stop Ebola
May. 21, 2018—A new Vanderbilt study suggests it may be possible to develop antibody therapies or a universal vaccine effective against multiple Ebola virus family members.
Hope for an RSV vaccine
Feb. 23, 2018—Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design.
Schaffner receives UpShot Award in vaccine communication
Jun. 15, 2017—The National Vaccine Program Office in the U.S. Department of Health and Human Services has selected William Schaffner, M.D., to receive its 2017 NVPO UpShot Award in Vaccine Communication.
Flu vaccine response in older adults
Jan. 25, 2017—High dose flu vaccine boosts the immune response in older adults by increasing activation of certain immune cells.
Improving vaccine formulations
Jan. 20, 2017—The compound MPLA is an attractive vaccine component, designed to elicit a robust immune response.
High-dose flu vaccine more effective in elderly, Vanderbilt-led study shows
Aug. 13, 2014—High-dose influenza vaccine is 24 percent more effective than the standard-dose vaccine in protecting persons ages 65 and over against influenza illness and its complications.
